Mauna Kea Technologies, a global optical biopsy company, recently conducted a study that showed its Cellvizio optical biopsy device had greater accuracy in detecting stomach cancer than traditional endoscopic biopsy.
The study conducted in Korea found that optical biopsy had a 91.7 percent accuracy rate in detecting stomach cancer, while traditional endoscopic biopsies had an 85.2 percent accuracy rate.
More Articles on Gastroenterology:
Memorial Hermann Northeast Hospital Names Dr. Howard Hamat Chief of Staff
CMS Requires Gastroenterologist to Document Quality of Care
Gastrointestinal Device Market Estimated at $33B by 2023
The study conducted in Korea found that optical biopsy had a 91.7 percent accuracy rate in detecting stomach cancer, while traditional endoscopic biopsies had an 85.2 percent accuracy rate.
More Articles on Gastroenterology:
Memorial Hermann Northeast Hospital Names Dr. Howard Hamat Chief of Staff
CMS Requires Gastroenterologist to Document Quality of Care
Gastrointestinal Device Market Estimated at $33B by 2023